<DOC>
	<DOCNO>NCT00153972</DOCNO>
	<brief_summary>The study design measure difference dopamine turnover rate measure Fluoro-Dopa-PET putamen patient Parkinson 's disease treat cabergoline levodopa 3 month . The study protocol include initial Fluoro-Dopa-PET scan treatment three month double-blind treatment cabergoline levodopa . The hypothesis study dopamine turnover rate sensitive marker early diagnosis Parkinson 's disease compare standard Fluoro-Dopa-PET measure Fluoro-Dopa uptake striatum . For interventional part study , hypothesis levodopa large effect striatal dopamine turnover compare dopamine agonist provide dopamine precursor . Enhancement compensatory mechanism dopamine loss early PD increase dopamine turnover could several beneficial implication improvement prolongation symptomatic treatment response , might also produce therapeutic problem development levodopa-induced motor complication .</brief_summary>
	<brief_title>Dopamine Turnover Rate Surrogate Parameter Diagnosis Early Parkinson 's Disease</brief_title>
	<detailed_description>The study design measure difference dopamine turnover rate measure Fluoro-Dopa-PET putamen patient Parkinson 's disease treat cabergoline levodopa 3 month . The hypothesis study dopamine turnover rate sensitive marker early diagnosis Parkinson 's disease compare standard Fluoro-Dopa-PET measure Fluoro-Dopa uptake striatum . The specific aim study estimate normal range test-retest measure various parameter characterise dopamine metabolism prolong 18F-dopa positron emission tomography ( PET ) measurement use reference tissue model compare value detection early PD . For interventional part study , hypothesis levodopa large effect striatal dopamine turnover compare dopamine agonist provide dopamine precursor . Enhancement compensatory mechanism dopamine loss early PD increase dopamine turnover could several beneficial implication improvement prolongation symptomatic treatment response , might also produce therapeutic problem development levodopa-induced motor complication . The specific aim evaluate effect levodopa dopamine D2 agonist cabergoline striatal dopamine turnover estimate inverse effective dopamine distribution volume ratio ( EDVR ) measure 18F-dopa PET de-novo PD . The study protocol include initial Fluoro-Dopa-PET scan treatment three month double-blind treatment cabergoline levodopa . This study investigator-blinded , randomized mono-center control phase IV study . The main inclusion criterion : - Early ( de novo ) Parkinson 's disease ( Hoen &amp; Yahr I II ) , accord UK brain bank criteria The main exclusion criterion : - Current past dopaminergic treatment - Atypical parkinsonian syndrome - Treatment neuroleptic ( present past ) Methods : - Fluoro-dopa-PET measuring dopamine turnover rate - clinical investigation include parkinsonian rating scale ( e.g . UPDRS , PDQ-39 , etc . ) - olfactory test Study medication : - Cabergoline ( 1 3 mg per day ) - Levodopa/carbidopa ( 50 300 mg levodopa per day one three dosage )</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Early ( de novo ) Parkinson 's disease ( Hoen &amp; Yahr I II ) , accord UK brain bank criterion Current past dopaminergic treatment Atypical parkinsonian syndrome Treatment neuroleptic ( present past ) Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Fluoro-Dopa-PET</keyword>
	<keyword>Dopamine agonist</keyword>
	<keyword>Cabergoline</keyword>
	<keyword>Surrogate marker</keyword>
	<keyword>Dopamine turnover</keyword>
</DOC>